Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Accumulated Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Accumulated Expenses for 10 consecutive years, with $83.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 33.83% to $83.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.9 million, a 33.83% increase, with the full-year FY2025 number at $83.9 million, up 33.83% from a year prior.
  • Accumulated Expenses was $83.9 million for Q4 2025 at Rhythm Pharmaceuticals, down from $84.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $84.5 million in Q3 2025 to a low of $7.2 million in Q1 2021.
  • A 5-year average of $42.6 million and a median of $40.0 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 36.6% in 2021, then soared 252.43% in 2022.
  • Rhythm Pharmaceuticals' Accumulated Expenses stood at $30.1 million in 2021, then increased by 9.34% to $32.9 million in 2022, then skyrocketed by 46.72% to $48.3 million in 2023, then rose by 29.83% to $62.7 million in 2024, then surged by 33.83% to $83.9 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Accumulated Expenses are $83.9 million (Q4 2025), $84.5 million (Q3 2025), and $69.2 million (Q2 2025).